Farnesyl diphosphate synthase (FDPS) is necessary for osteoclast survival and activity and is considered as a major molecular target of aminobisphosphonates. Our objective was to analyze the influence of FDPS polymorphisms on bone mineral density (BMD) and the response to antiresortive drugs. Three single-nucleotide polymorphisms of FDPS were analyzed in 1186 postmenopausal women. There was only a marginally significant association of baseline hip BMD with rs11264359 alleles (P ¼ 0.043). However, among 191 women receiving antiresortive therapy, there was a very significant association between rs2297480 or rs11264359 alleles and the BMD changes after aminobisphosphonate therapy for an average period of 2.5 years (P ¼ 0.001). The genotype explained 7.2% of the variance in the BMD response. On the other hand, there was no association between the BMD changes after raloxifene therapy and any of the polymorphisms studied. These results suggest that common polymorphisms of the FDPS gene influence the response to aminobisphosphonates.
Introduction
Osteoporosis is a frequent skeletal disorder, particularly among postmenopausal women. 1 It is characterized by reduced bone mass and alterations in the bone microarchitecture, which result in an impaired bone strength and propensity to fracture. The decreased bone mass is the consequence of an imbalance in the bone remodelling process. Bone is continuously remodelled by the so-called 'bone remodelling units', composed of groups of osteoclasts and osteoblasts that resorb small volumes of tissue to be later replaced by newly synthesized bone. Bone remodelling starts at a given site when a group of osteoclasts, derived from precursors in the hematopoietic lineage, is activated and begins to resorb bone tissue. This phase of bone resorption is followed by the formation of new bone by osteoblasts, cells that derive from mesenchymal precursors.
are nowadays the most widely used antiosteoporotic drugs. These drugs inhibit osteoclast function by interfering the mevalonate pathway, and particularly, the critical enzyme farnesyl diphosphate synthase (FDPS, also known as farnesyl pyrophosphate synthase or FPPS). As a result of this inhibitory effect, aminobisphosphonates prevent the biosynthesis of isoprenoid lipids (farnesyl diphosphate and geranylgeranyl diphosphate), which are essential mediators for the post-translational prenylation of several proteins, including various GTPase signalling factors. The loss of prenylated proteins induces cellular dysfunction and, indirectly, osteoclast death by apoptosis.
11,12 These studies on the mechanism of action of aminobisphosphonates have revealed the important role of FDPS to maintain the resorption activity of the osteoclasts. Several investigators have shown effects of bisphosphonates on the bone-forming osteoblasts in vitro, but their actual importance in vivo is still unclear. 13 Osteoporosis is a complex disease, resulting from the interaction of genetic and acquired factors. In fact, hereditary factors have been reported to explain between 50 and 80% of the variance of bone mineral density (BMD). However, the genes involved have not been completely elucidated. 14, 15 Similarly, little is known about the pharmacogenomics of osteoporosis, and specifically about the possible influence of genetic factors on the therapeutic effects of antiosteoporotic drugs. 16 The aim of this study was to analyze the influence of FDPS polymorphisms on BMD and the response to antiresorbing drugs.
Subjects and methods

Subjects
We studied 1186 postmenopausal women living in Cantabria, a region in Northern Spain. They included volunteers recruited by advertisements, women taking part in an epidemiological study of osteoporosis risk factors and women sent to our clinic because of osteoporosis concerns. BMD was measured by dual-energy X-ray absorptiometry using a Hologic QDR 4500 densitometer. Participants gave informed consent and the study was approved by the Clinical Research Ethical Committee of the Hospital UM Valdecilla.
In the pharmacogenetic study, we included 191 women with osteoporosis who had BMD measured at baseline and after treatment with antiresortive drugs (alendronate, risedronate or raloxifene) for at least 12 months. Most of them (490%) were also given vitamin D and calcium supplements.
Genotyping
The Hapmap database was explored to identify singlenucleotide polymorphisms (SNPs) of the FDPS region in the Caucasian population. Then, tag-SNPs were selected using the algorithms available in Haploview with the 'aggressive tagging' option. 17 In addition, we included some SNPs with potential regulatory function as assessed by the bioinformatic suite Pupa. 18, 19 Thus, we studied four SNPs: rs2297480, located in the 5 0 region of FDPS gene, 778 bp upstream of the translation start site; rs11264359, an intronic SNP at þ 4125 from the translation start site; rs17367421, located in an intron at þ 8543; and rs17456, a non-synonymous coding polymorphism at þ 11 607. DNA was isolated from peripheral blood by using column-based commercial methods and the alleles at each locus were genotyped by using specific primers and Taqman probes included in commercially available assays (Applied Biosystems, Foster City, CA, USA).
Data analysis
The response of BMD to drug therapy was estimated as the average annual percent change, with the formula:
where BMD 1 is baseline BMD, BMD 2 is BMD after therapy and Interval is the time period between both BMD measurements (in years). 20, 21 Haplotypic blocks were estimated by the method of Gabriel, implemented in Haploview. 17 The departure from Hardy-Weinberg equilibrium was tested with the HWSIM software (http://krunch.med.yale.edu/hwsim/hwsim.doc). The association of alleles with baseline BMD and with the BMD response to antiresorptive drugs was studied by analysis of variance and adjusted by analysis of covariance and multiple linear regression. The proportion of variance explained by the genotypes was estimated as the r 2 coefficient in the linear regression models. Power estimates were obtained with the QUANTO v1.2.3 software (available at: http://hydra.usc.edu/gxe/). Thus, we estimated that the study had a 99% power to find a genotype influence explaining at least 2% of baseline BMD variance. For the pharmacogenetic study, the power to detect a genetic influence explaining 5 or 10% of the variance of BMD change after bisphosphonate therapy was 77 and 97%, respectively. The corresponding values after raloxifene therapy were 35 and 62%, respectively. Uncorrected nominal P-values are shown, unless otherwise indicated. As we analyzed three SNPs (see below), the Bonferroni-corrected P-value threshold for statistical significance was 0.016.
Results
Genotype frequencies and baseline BMD
The average age of the women studied was 66 ± 9 years (range 43-89 years) and body mass index was 28.1±4.6 kg m À2 (Table 1) . Table 2 shows the genotype frequencies. All were consistent with Hardy-Weinberg equilibrium. After genotyping the rs17456 locus in a preliminary set of 500 women, it showed a very low diversity, with a minor allelic frequency of only 0.3%. Therefore, it was not analyzed further. The genotyping rate of the remaining three polymorphisms was 97.3%. They were in strong linkage disequilibrium (rs11264359-rs2297480, Po1 Â 10
À10
; rs17367421-rs11264359, P ¼ 0.003; rs17367421-rs1197480, P ¼ 0.005; Figure 1 ). Alleles at the rs2297480 and rs17367421 loci were not associated with BMD. There was a trend for association of BMD with the rs11264359 alleles (Figure 2 ), with nominal P-values of 0.043 at the hip and 0.07 at the spine, which did not reach the multiple test-adjusted threshold for significance.
Pharmacogenetic study
We included 191 patients with two BMD measurements at the hip; seven of them received two cycles of therapy; therefore, we analyzed 198 treatment periods. Drugs used were alendronate (n ¼ 109), risedronate (n ¼ 39) and raloxifene (n ¼ 50). Most women had primary osteoporosis (n ¼ 168). The most common secondary causes of osteoporosis were hyperthyroidism (n ¼ 5), hyperparathyroidism (n ¼ 3) and glucocorticoid therapy (n ¼ 5). The mean interval between BMD measurements was 2.5 years (1-2 years, 17% women; 2-3 years, 63%; 3-4 years, 14%; more than 4 years, 6%). Six outliers with absolute annual changes in BMD over 6.5% (three cases 46.5% and three cases oÀ6.5%) were excluded from further analyses.
Among aminobisphosphonates-treated women, 89% experienced an increase in spine BMD (0.1-3% per year in 56%, and 43% per year in 33%) and 68% experienced an increase in total hip BMD (0.1-3% per year in 59%, and more than 3% per year in 9%). There was a significant association between rs2297480 alleles and hip BMD changes induced by aminobisphosphonates (P ¼ 0.001, Figure 3) , which was independent of the drug (Table 3 ) and the interval between BMD measurements (not shown). The genotype explained 7.2% of the variance in the BMD response to aminobisphosphonates. The rs11264359 polymorphism was in complete linkage disequilibrium with the rs2297480 locus. Consequently, rs11264359 was similarly associated with drug response (Figure 3) . However, there was no association between alleles at the rs17367421 locus and changes in BMD after aminobisphosphonates. BMD changes at the lumbar spine showed a trend to vary across genotypes similar to that observed at the hip, but it did not reach statistical significance. Among raloxifenetreated women, 71% gained BMD at the spine (0-3% per year in 65%, and more than 3% per year in 6%) and 53% at the hip (0-3% per year in 47%, and more than 3% per year in 6%). There was no association between the BMD changes 
From dairy products. after raloxifene therapy and any of the polymorphisms studied (Table 3) .
Discussion
Osteoporosis has a strong hereditary component and represents an important health problem among postmenopausal women. Therefore, there is a great interest in elucidating the genetic factors involved, and doing so, to identify high-risk individuals who become a target population for preventive strategies. In fact, hundreds of candidate gene studies and a few genome-wide studies have been performed during the past 15 years. However, the results are somewhat disappointing and, as it also happens with other complex disorders, only a minor proportion of the disease risk is explained by the genetic loci so far identified. 22 Several anabolic and antiresorptive drugs are available to treat osteoporosis. Some of them have been shown to increase BMD and decrease the risk of vertebral fractures roughly by 50%, and the risk of peripheral fractures by 20-30%, approximately. Therefore, there is a clear need for better therapeutic strategies, either by synthesizing more active drugs or by tailoring therapy to the individual characteristics of patients, including the genetic ones. However, the pharmacogenetic information on antiosteoporotic drugs is still scanty.
A few investigators have explored the association of polymorphisms of genes related to bone homeostasis, albeit not specifically bisphosphonate targets, with drug response. They included the vitamin D receptor, estrogen receptors, collagen and lipoprotein receptor-related protein (a Wnt coreceptor), but the results have not been adequately replicated. 16, 23, 24 In this study, we analyzed the relationship of several polymorphisms of the gene encoding the FDPS enzyme, a major target of aminobisphosphonates, with BMD and drug response in postmenopausal women. We only found a quantitatively small and not significant trend for association of one of the SNPs studied with baseline hip BMD. Levy et al. 25 also reported a marginally significant association of one SNP included in our study (rs2297480) and BMD in a group of 283 postmenopausal women aged 65 years or older. The direction of the effect was the same in our study and in Levy's, with lower BMD in women with the minor allele. Overall, these results would suggest that the allelic variants of FDPS may have a small influence on BMD, but replication in other populations is needed.
Interestingly enough, despite the absence of important differences in baseline BMD, we found a marked association between the FDPS genotype and the response to aminobisphosphonates. In fact, whereas women with the common AA genotype at the rs2297480 loci gained 1% per year of BMD, the CC homozygotes lost about 1.6%, and the heterozygotes had an intermediate response. Therefore, our results suggest a strong pharmacogenetic influence. A similar influence was found when the rs11264359 polymorphism was analyzed. As both polymorphisms are tightly linked, we cannot elucidate which one is actually causing the association. Nevertheless, our results are consistent with other report by Marini et al., 26 who also found a smaller response of bone remodelling markers in Caucasian women with CC genotypes at rs2297480, as well as a nonstatistically significant lower BMD response. However, in a study of Korean women, Choi et al. 27 did not find an association of two SNPs of FDPS with the BMD response after 12 month of bisphosphonate therapy. However, they found an association with an insertion/deletion polymorphism of the gene encoding geranylgeranyl diphosphate synthase (GGPS1), another enzyme in the mevalonate pathway that may also be inhibited by aminobisphosphonates. We can speculate that the different results depend on ethnic differences between Asians and Caucasians. In fact, it is worth mentioning that whereas A is the major allele at the rs2297480 locus in the Hapmap Caucasian database, C is the major allele in Asians. On the other hand, the BMD increase reported by Choi et al. 26 is higher than the response found in our study and in other studies in Caucasians.
Our study has several limitations. Some of them are related to the size of the study group, which limits the statistical power, particularly with regard to the response to raloxifene, and the possibility of performing subgroup analyses. Thus, we could not separate women receiving daily or weekly doses of bisphosphonates. Although patients were regularly followed in the outpatient clinic to reinforce drug adherence and check for possible adverse effects, we do not have specific data about drug compliance and persistence, and consequently about their influence on drug response. As reported in other regions, in this study calcium intake was below the current recommendations. We do not have complete information on vitamin D status, which has been reported to influence the response to antiresorbing drugs. 28 Therefore, we do not know whether low calcium/ vitamin D availability actually impaired the drug response. However, the great majority of patients received calcium and vitamin D supplements, and there is no clear biological rationale suggesting an influence of FDPS polymorphisms on vitamin D levels. Therefore, those factors are unlikely to confound the observed association between the genotype and drug response. As an important limitation, we could not analyze the possible influence of the genotypes on the risk of fractures, which are the clinically relevant end point of osteoporosis, only partially captured by BMD analysis. 29, 30 The mechanisms involved in the genotype-related differences remain to be elucidated. In silico analysis of the rs2297480 and rs11264359 polymorphisms using the FastSNP web tool suggests that their alleles may differ in the ability to bind certain transcription factors, such as Aml-1 and CdxA. However, in vitro functional studies are needed to establish their functional consequences with certainty. Polymorphisms of the FDPS gene are in strong linkage disequilibrium. Therefore, it is hard to know which one of the SNPs included in our study, or other neighborlinked polymorphisms, are actually causing the different drug responses. Whatever the mechanism might be, it seems to be specifically related to aminobisphosphonates, as there was no indication of genotype-related differences in the BMD changes after raloxifene therapy.
In conclusion, this study suggests that some common polymorphisms of the FDPS gene, encoding an aminobisphosphonate target enzyme of the mevalonate pathway, influence the response to these drugs, but they have no influence on the response to raloxifene. If the results are confirmed in other population groups, they could become part of a strategy to individualize antiresorptive therapy.
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